MedPath

GALNT4 in Patients With Acute Coronary Syndrome

Completed
Conditions
Acute Coronary Syndrome
Interventions
Diagnostic Test: expression of GALNT4
Registration Number
NCT03335514
Lead Sponsor
The First Affiliated Hospital of Dalian Medical University
Brief Summary

The expression of GALNT4 in blood with acute coronary syndrome

Detailed Description

Emerging evidences have linked GALNTs to cardiovascular disease or susceptibility to CAD.GALNT4, a member of the GalNAc-Ts family,contributes to the initiation of O-linked. Polymorphisms in GALNT4 have been linked with incidence of MI in an Irish population, probably that O-glycosylation of PSGL-1 by GalNAc-T4 may be important for many P-selectin mediated inflammation.However, there is few relevant studies about the expression of GALNT4 in patients with acute coronary syndrome.This study valuates the expression of GALNT4 in patients with acute coronary syndrome.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • diagnosed as acute coronary syndrome,including STEMI,NSTE-ACS,or diagnosed as SAP by CAG.

    • with left ventricular ejection fraction(LVEF)>=45%
    • written informed consents are obtained
    • admitted within 24 hours after chest pain attacked(except SAP)
Exclusion Criteria
  • • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy

    • complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
    • with acute or chronic infection, surgery or trauma in the last month
    • secondary hypertension, severe liver dysfunction,severe renal insufficiency
    • with abnormal thyroid function or allergy to iodine agent
    • refusal to sign the informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CONTROLexpression of GALNT420 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
STEMIexpression of GALNT4The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
NSTE-ACSexpression of GALNT4The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
SAPexpression of GALNT4The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
Primary Outcome Measures
NameTimeMethod
the expression of GALNT412 months

Realtime RCR measure the expression of galnt4 in peripheral blood

Secondary Outcome Measures
NameTimeMethod
MACEs during 12-month follow-up12 months

All major adverse cardiac events( MACEs) including death, myocardial infarction, heart failure are recorded

Trial Locations

Locations (1)

The First Affiliated Hospital of Dalian Medical University

🇨🇳

Dalian, Liaoning, China

© Copyright 2025. All Rights Reserved by MedPath